### **Overview** Emcure Pharmaceuticals Ltd. (EPL), established in 1981 and headquartered in Pune, India, is the **12th largest pharmaceutical company in India by domestic sales** (as of MAT June 2024). The company operates in over **70 countries**, with a geographically diversified revenue base anchored in India, Europe, Canada, and emerging markets. Emcure is transitioning into a more strategic, science-led, innovation-driven organization under the "Emcure 2.0" transformation, a 5-year roadmap initiated in FY26 aimed at accelerating growth, improving margins, and enhancing return on capital employed (ROCE). Emcure follows a **vertically integrated business model** with in-house capabilities spanning **API manufacturing, formulation development, and biologics production**, enabling end-to-end control over its value chain and rapid commercialization of differentiated products. --- ### **Business Model & Operations** - **Vertically Integrated Structure**: The company controls the full pharmaceutical value chain — from API synthesis to finished dosage forms and biologics. This integration enhances cost efficiency, quality control, and speed-to-market. - **Manufacturing Infrastructure**: - Operates **13 advanced manufacturing facilities** in India across Pune (Kurkumbh, Pimpri), Hinjawadi, Jammu, Sikkim, and Mehsana. - Two API plants (Kurkumbh, Pimpri) are approved by USFDA, EDQM, UK-MHRA, EU-GMP, and WHO. - Facilities support a wide range of dosage forms: oral solids, liquids, lyophilized and liposomal injectables, cytotoxic drugs, peptides, and biologics. - The company is a pioneer in **continuous biomanufacturing** and mRNA vaccine production through its subsidiary **Gennova**. - All plants maintain compliance with global regulatory standards, with no major regulatory issues over the last five years. --- ### **Revenue Segmentation & Geographic Presence** Emcure has achieved a **near 50:50 split between domestic and international revenues**, providing strong geographical diversification: - **International Markets (FY25: 54% of total revenue)** - **Canada/North America**: Revenue of Rs. 12,520 million (up 35.7% YoY), driven by the integration of **Mantra Pharma**, which enabled pan-Canada presence including Quebec. - **Europe**: Contributed Rs. 14,738 million. Growth is being powered by **Tillomed Laboratories** (UK), approvals for **Liposomal Amphotericin B**, and the acquisition of **Manx Healthcare’s portfolio** (100+ products). - **Rest of World (RoW)**: Revenue reached Rs. 15,105 million, growing 27.9%. Strong demand in ARV and non-ARV segments, especially in LATAM, MENA, and Asia-Pacific. - **India (46% of FY25 revenue)** - Domestic revenue stood at Rs. 36,597 million, growing 16.4% YoY. - Key drivers: Expansion in **gynecology**, **cardiovascular**, and **dermatology**, and the integration of **Sanofi’s cardiovascular portfolio**. --- ### **Therapeutic Focus & Product Portfolio** Emcure has a **therapy-focused, science-led portfolio** across chronic and acute care, with increasing emphasis on high-value chronic therapies: #### **Core Therapeutic Areas** 1. **Women’s Health & Gynecology** - Leadership in **anemia** (Orofer XT – #1 brand), **PCOS, menopause, and fertility**. - Expanded via product launches and patient education programs (e.g., EmSakhi for diabetes in women). - 57% of Indian women suffer from anemia (NFHS-5) – a key unmet need driving long-term growth. 2. **Cardiovascular & Metabolic Diseases** - Anchor brands: **Amaryl, Cetapin, Tenectase**. - Strategic partnership with **Sanofi** to distribute key CV drugs (Cardace®, Clexane®) in India. - Filing for **recombinant Asparaginase**, first Indian-made version, expected within 6 months. 3. **Oncology & High-Potency Products** - Core platform: **High-Potency API and Injectable Manufacturing**. - Products: Eribulin, Carmustine, Irinotecan, Melphalan. - Developing **Antibody-Drug Conjugates (ADCs)**, leveraging Gennova’s antibody tech and internal linker expertise. 4. **Anti-Infectives / HIV (ARVs)** - In-licensed **Lenacapavir** (Gilead Sciences) – a **6-month dosing** ARV, positioning Emcure as a global leader in long-acting HIV therapy. - One of only six global licensees; plans for affordable access in underserved regions. 5. **Biosimilars & Biologics** - **Gennova Biopharmaceuticals**, a subsidiary, leads innovation in biologics and mRNA technology. - Achievements: - World’s first **thermostable mRNA COVID-19 vaccine** (2–8°C). - Published in *Nature Medicine*; received **Emergency Use Authorization (EUA)**. - Secured **$13.38 million CEPI grant** for mRNA-based Nipah virus vaccine. - Recombinant **Asparaginase** (oncology) and **Bevacizumab** (ophthalmology) under regulatory review. 6. **Complex Generics & Injectables** - **Liposomal Amphotericin B**: - First generic approval in **UK and EU**, a major regulatory milestone. - Positioned for high-margin, high-demand use in fungal infections. - Filed in RoW markets; key product for FY26–27 commercialization. - Launching **ready-to-use (RTU) Bevacizumab** for **wet AMD**, with patented delivery device; expected to launch in FY26. 7. **Dermatology** - Launched **Emcutix Biopharmaceuticals (Oct 2024)** – wholly owned subsidiary focused on skin health. - Appointed **G. Sathya Narayanan** (ex-Galderma) as Chief. - Portfolio includes: - **Flawlizo** (anti-acne, microsphere tech) - **PRX-PLUS™** (in-licensed from **WiQo, Italy**) – non-invasive, needle-free skin treatment; used in 8M+ procedures globally. - **SOLGLO®**, **AquaOat**, and urea-based emollients. - Indian derma market valued at **$3.6B**; Emcutix targeting underpenetrated segments. 8. **Consumer Wellness & OTC** - Launched **Arth™** (wellness supplements for sleep, intimacy, cognition, nutrition) and **Galact®** (post-pregnancy lactation support). - Collaborated with **actress Vidya Balan** as brand ambassador for women’s wellness. 9. **Ophthalmology (Emerging Segment)** - Development of **biosimilar Bevacizumab** for **wet AMD**. - Phase III trials ongoing; planned launch in FY26. - Patent-protected delivery system differentiates from competitors. --- ### **Research & Development (R&D)** - **Platform-Driven Innovation**: Emcure’s R&D is built on **four core platforms**: 1. **Chirality** (e.g., improved CV drugs) 2. **Iron-Based** (women’s health compliance) 3. **High-Potency Products** (oncology APIs) 4. **Biologics** – microbial & mammalian expression (oncology, CNS, nephrology) - **R&D Strength**: - **548+ scientists**, including **48 PhDs**. - **220+ granted patents**, showcasing depth in innovation. - **Emcure Research Centre (Gujarat)**: Focused on NDDS, inhalers, injectables, topicals. - AI integration: - AI assistant for regulatory filings & pharmacovigilance. - AI-ML for root cause analysis and sales intelligence. - **Strategic Pipeline Focus**: - **GLP-1 analogs**: **Semaglutide** development underway for **Day-1 launch in India (2026 patent expiry)**. - **Long-Acting Injectables (LAIs)**, **NDDS**, **ADCs**, **Peptides**. - **Liposomal respiratory product** in advanced development. --- ### **Growth Strategy & M&A** Emcure’s growth is driven by **organic innovation, in-licensing, and strategic acquisitions**: - **Tillomed Laboratories (Europe)**: Foundation for EU market presence. - **Mantra Pharma (Canada)**: Achieved pan-Canadian footprint; 110 products launched. - **Manx Healthcare (UK, Oct 2025)**: Acquired 100+ product dossiers, >50 non-commercialized – strengthens EU pipeline. **In-licensing & Partnerships**: - Gilead (Lenacapavir) - Sanofi (CV portfolio in India) - WiQo (PRX-PLUS) --- ### **Financial & Operational Highlights (FY25)** - **Revenue Growth**: - **International**: **20.5% YoY growth**, led by Canada (+35.7%) and RoW (+27.9%). - **Europe**: Recovery underway with key approvals. - **Manufacturing Innovations**: - Digital BMRs, automated audit trails, flow chemistry, green chemistry. - De-bottlenecking and capacity expansions in Mehsana (injectables) and Kurkumbh (API). - **Regulatory Excellence**: - No plant failures in 5 years across USFDA, EU-GMP, MHRA, Health Canada. - Biologics plant received **EU accreditation** – enables faster emerging market approvals.